TABLE 4.
Prevalence of MDR isolates and predominant MDR phenotypes in centralized in vitroa and TSN Database-USAb surveillance data
| Organism | In vitro surveillance results
|
TSN surveillance results
|
||||
|---|---|---|---|---|---|---|
| n | No. (%) of MDR isolates | Predominant MDR phenotype (%)c | n | No. (%) of MDR isolates | Predominant MDR phenotype (%)c | |
| E. coli | 709 | 30 (4.2) | AMP, SXT, FQ (46.7) | 43,085 | 1,341 (3.1) | AMP, SXT, FQ (39.9) |
| K. pneumoniae | 584 | 20 (3.4) | CAZ, GEN, SXT (45.0) | 7,485 | 550 (7.3) | CAZ, GEN, SXT (42.2) |
| P. mirabilis | 413 | 10 (2.4) | AMP, GEN, SXT (70.0) | 6,938 | 378 (5.4) | AMP, SXT, FQ (40.0) |
| E. cloacae | 323 | 21 (6.5) | CAZ, GEN, SXT (52.4) | 3,311 | 196 (5.9) | CAZ, GEN, SXT (53.6) |
| Citrobacter spp. | 204 | 1 (0.5) | CAZ, GEN, SXT (100.0) | 2,155 | 112 (5.2) | CAZ, GEN, SXT, FQ (42.9) |
| S. marcescens | 196 | 2 (1.0) | CAZ, GEN, SXT (50.0) | 2,035 | 12 (0.6) | CAZ, GEN, SXT, FQ (41.7) |
| E. aerogenes | 183 | 0 (0.0) | 1,559 | 39 (2.5) | CAZ, SXT, FQ (35.9) | |
| Providencia spp. | 72 | 2 (2.8) | CAZ, SXT, FQ (50.0) | 448 | 27 (6.0) | GEN, SXT, FQ (77.8) |
| Enterobacteriaceae | 2,684 | 86 (3.2) | 67,016 | 2,655 (4.0) | ||
| P. aeruginosa | 464 | 17 (3.7) | CAZ, GEN, IPM, FQ (58.8) | 15,171 | 959 (6.3) | GEN, IPM, FQ (28.3) |
a
Organisms collected between 1 January and 31 March 1999.
b
Data collected from 1 January 1998 to 31 March 1999.
c
AMP, ampicillin; CAZ, ceftazidime; GEN, gentamicin; IPM, imipenem.